Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
ConditionColorectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTempus AI
About this trial
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Eligibility criteria
Qualifiers
Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
18 years old or older
Willing and able to provide informed consent
Disqualifiers
Not willing to have additional blood samples collected
Pathology that is not consistent with colorectal adenocarcinoma
Trial design
Treatments tested in this trial
- Observation
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov